Indivior Welcomes Tony Kingsley to Its Board of Directors
Indivior PLC (NASDAQ: INDV) has officially announced the addition of Tony Kingsley to its Board of Directors as an Independent Non-Executive Director. This strategic appointment is effective immediately. Kingsley brings with him an impressive background and considerable expertise in the biopharmaceutical landscape, aligning with Indivior's mission and objectives.
Professional Background of Tony Kingsley
Kingsley is known for his significant contributions in the biopharmaceutical industry, demonstrating a robust track record of leadership in various scientific and therapeutic domains. His prior roles include being the CEO of Stablix, Inc. and President of Scholar Rock, where he has been instrumental in guiding companies through critical stages of development.
Leadership and Experience
With an extensive career that spans several high-profile executive positions, Kingsley has accumulated a wealth of experience. His tenure includes leadership roles at TARIS Bio, where he oversaw the company's acquisition by Janssen Pharmaceuticals. Additionally, he served as the Executive Vice President of Global Commercial Operations at Biogen, where he played a key role in launching numerous successful therapies.
Driving Growth at Indivior
Indivior Chair, David Wheadon, M.D., expressed his enthusiasm about Kingsley’s appointment, highlighting his operational expertise and strategic vision. According to Wheadon, Kingsley will be instrumental in advancing the development and commercialization of Indivior's leading product, SUBLOCADE.
Building on Indivior’s Mission
Reflecting on his new role, Kingsley emphasized his commitment to addressing the opioid use disorder crisis. He has voiced his dedication to working collaboratively with the Board and management to elevate Indivior’s position as a pivotal leader in the field of opioid recovery treatments.
Indivior's Commitment to Treatment
Indivior has been proactive in its commitment to addressing opioid use disorders through its advanced portfolio of medicines. The company works on transformative treatments to navigate what has become a significant global health issue.
Company Vision and Future Goals
Indivior aims to ensure that patients worldwide have access to evidence-based treatment options. With a strong pipeline of candidates in development, the company is well-positioned to enhance its offerings and cater to the diverse needs of those battling opioid addiction.
About Indivior
As a global pharmaceutical company, Indivior continues to prioritize the health and well-being of patients dealing with opioid use disorders. With its headquarters in the United States and a global team of over 1,000 members, Indivior remains dedicated to improving access to quality treatment. Its extensive portfolio is currently available in over 30 countries, emphasizing its reach and commitment to tackling this chronic disease effectively.
Frequently Asked Questions
Who is Tony Kingsley?
Tony Kingsley is a seasoned biopharmaceutical executive recently appointed as an Independent Non-Executive Director at Indivior PLC.
What is Indivior's main focus?
Indivior focuses on developing innovative medicines to treat opioid use disorder, enhancing recovery possibilities for patients.
What previous roles did Tony Kingsley hold?
He has served as CEO of Stablix and President of Scholar Rock, among other significant leadership positions in the biopharmaceutical sector.
What is the significance of Kingsley’s appointment?
His appointment strengthens Indivior's Board, bringing in valuable expertise that can drive growth and innovation in treatment solutions.
How does Indivior plan to expand its efforts in OUD treatments?
Indivior is actively developing a robust pipeline of products aimed at addressing the challenges of opioid use disorder effectively.
